8 European nations including Italy, Latvia, Luxembourg, Lithuania, Estonia, Denmark, Norway and Iceland have decided to stop using the AstraZeneca COVID-19 vaccine due to serious blood clot incidents reported in many countries.
Must Watch: Would you live on 3D Printed Mars for a year for $60,000?
Iceland has become the latest European nation to suspend the AstraZeneca jab.
The tiny island nation has confirmed roughly 6,000 COVID cases since the start of the pandemic, which is roughly 2% of the population.
Meanwhile, the EMA (the European equivalent of the FDA) confirmed that it has counted no fewer than 30 incidents of harmful blood clots in patients who received the vaccine, including at least one case in Denmark where the patient died.
The reason for halting the AstraZeneca COVID-19 vaccine is due to reports of serious blood clots after vaccination.
Subscribe to GreatGameIndia
As per tweet of writer and skeptic Alex Berenson, this is not the only vaccine that causes adverse effects.
Alex Berenson tweeted “Just wait until they hear what the mRNA vaccines can do… Really, though, the side effect profile of the @astrazeneca vaccine is hardly worse than the mRNA shots, but somehow it has faced much more scrutiny. Follow the politics, I mean science.”
Health minister of Denmark confirmed the suspension of AstraZeneca Jabs via tweet. He said “there’s currently no ways to know for certain whether the cases of serious blood clots are connected to the vaccine, but the situation certainly warrants more investigation. We acted early, it needs to be thoroughly investigated.”
Italian PM Mario Draghi halted a shipment of AstraZeneca jabs to Australia. Health authorities in Italy are suspending jabs from current batch of vaccine. On the other hand, health authorities in London and Brussels dismissed these issues, insisting that this vaccine is safe while going with plans to approve Johnson & Johnson’s single-dose jab.
BREAKING: Johnson & Johnson receives positive opinion for its #COVID19 vaccine from the Committee for Medicinal Products for Human use of the European Medicines Agency, paving the way for approval in the EU. $JNJ— Julianna Tatelbaum (@CNBCJulianna) March 11, 2021
The EU medicines regulator said it was recommending the vaccine be authorized for all adults over 18 “after a thorough evaluation” of JNJ’s data found the vaccine met the criteria for efficacy, safety and quality. The JNJ jab is the fourth to be licensed for use inside the EU.
Health authorities in Denmark are so much worried about the adverse side effects believed to be related with AstraZeneca vaccine. Now Danish authorities also suspended AstraZeneca shot on Thursday. Many patients have reported cases of blood clots they received after getting vaccinated. This suspension will last for 2 weeks.
NEW: Danish Health Authority says use of #AstraZeneca COVID19 #vaccine has been halted due to serious cases of blood clots. This follows similar suspension in Austria.— Julianna Tatelbaum (@CNBCJulianna) March 11, 2021
Here's a statement from the European Medicines Agency on the issue yesterday: pic.twitter.com/69WBgoujV1
As per European medicines agency, there are no evidences that link blood clots with the vaccine. The company said only 22 cases of adverse events have been noticed and approx 3M people have been vaccinated.
One investor claimed Denmark’s suspension of AstraZeneca COVID-19 vaccine on blood clot concerns shows “the detection systems that look for potential safety issues are working,” and that most of these “safety events” would ultimately be linked to natural processes, not the jab.
“It’s good to see the safety signal detection systems working and it’s important that any safety signal is followed-up using the correct protocols,” Shore analyst Adam Barker told Bloomberg. Data from the vaccine’s phase three trials suggests that “you would expect that most safety signals won’t ultimately be linked to the vaccine,” he said.
However, “it’s hard to make judgments on the impact on shareholder value,” he added, given there are “a lot of moving parts.” But ultimately, a risk-reward trade-off with any therapy; “you can only confidently make judgments on that decision when all the data is finalized and clear”.
Recently, a 65-year-old man in India collapsed and passed away just five minutes after getting first dose of vaccine against covid-19. He was injected with 0.5 ml dose of Oxford AstraZeneca vaccine Covishield intramuscularly.
Even Australia’s Health Minister Greg Hunt in charge of rolling out Australia’s coronavirus vaccine program was hospitalized just one day after taking the AstraZeneca COVID-19 vaccine.
According to a report by Germany’s Standing Vaccination Commission, the Oxford-AstraZeneca COVID-19 vaccine is only effective 8% in people over 65.
Three European countries of Sweden, France and Germany have decided not to use AstraZeneca COVID-19 vaccine for people over 65. This decision was made due to the lack of data available about its effectiveness in elderly people.
For latest updates on the outbreak check out our Coronavirus Coverage.